Kriya Therapeutics, founded in 2019, has raised $921.3 million across Seed, Series A, Series B, Series C, and Series D funding rounds, reaching a $2 billion valuation. Its largest round was a $386.3 million Series D in 2023 led by Bain Capital Life Sciences. Kriya Therapeutics develops gene therapies targeting chronic diseases, with a focus on liver and ocular indications. Backed by leading life sciences investors, the company is advancing multiple clinical programs with the goal of delivering long lasting gene based treatments.